Scotiabank analyst Louise Chen initiated coverage of Regeneron (REGN) with a Sector Perform rating and $650 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron: Strong Buy Rating Backed by Robust Business and Promising Oncology Developments
- Regeneron’s Innovative Anticoagulation Advancements and Market Potential Drive Buy Rating
- Regeneron treatment of pulmonary arterial hypertension granted orphan status
- Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study
- Regeneron, Sanofi announces presentation of Phase 3 trial of Dupixent